<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261517</url>
  </required_header>
  <id_info>
    <org_study_id>HC-COVID-19</org_study_id>
    <nct_id>NCT04261517</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19</brief_title>
  <official_title>Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of
      COVID-19 pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no vaccine or antiviral treatment for human coronavirus, so this study aims to
      evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19
      pneumonia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3</measure>
    <time_frame>3 days after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5</measure>
    <time_frame>5 days after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</measure>
    <time_frame>7 days after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The mortality rate of subjects at weeks 2</measure>
    <time_frame>14 days after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>14 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The critical illness rate of subjects at weeks 2</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pneumonia, Pneumocystis</condition>
  <condition>Coronavirus</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine and conventional treatments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatments</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After randomization, subjects take conventional treatments without hydroxychloroquine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments</description>
    <arm_group_label>Hydroxychloroquine and conventional treatments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participants were diagnosed as COVID-19 pneumonia, according to the notice on
             printing and distributing the diagnosis and treatment plan of pneumonia with new
             coronavirus infection (trial version 4 or update version) made by National Health
             Commission of the People's Republic of China;

          -  Participants aged over 18;

          -  Written the informed consent.

        Exclusion Criteria:

          -  Hypersensitivity to chloroquine or hydroxychloroquine;

          -  Women during pregnancy;

          -  Severe heart, lung, kidney, brain, blood diseases or other important systemic
             diseases;

          -  Participants with retinal disease, hearing loss;

          -  Participants with severe neurological and mental illness;

          -  Subjects were considered to be unable to complete the study, or not suitable for the
             study by researchers.

        Exit criteria:

          -  Subjects asked to withdraw the study

          -  Subject will benefit if withdraw according to researchers' suggestions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03</url>
    <description>The results have been published on the Journal of Zhejiang University (Medical Sciences)</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>COVID-19</keyword>
  <keyword>hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

